

Antiviral Therapeutics

Technologies, Companies & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is the CEO and a consultant at Jain PharmaBiotech. Prof. Jain's 478 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include a Handbook of Nanomedicine (2008, Chinese edition published by Peking University Press in 2011, 3rd ed by Springer in 2017), Textbook of Personalized Medicine (2009; Japanese ed 2012; 2nd ed Springer 2015), Handbook of Biomarkers (2010; Chinese edition, Chemical Industry Press 2016, 2nd ed 2017), "Applications of Biotechnology in Cardiovascular Therapeutics" (2011), "Applications of Biotechnology in Neurology (2013)", and "Applications of Biotechnology in Oncology (2014)", all of which have been published by Springer.

**November 2018 (originally published in 2007 and continuously updated since then)
Copyright © 2018 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	17
1. Introduction to Virology	19
Introduction	19
Evolution of viruses	19
Virus databases	19
A practical classification of viruses	19
The human virome	21
Viral genomics	21
Pathomechanism of viral diseases relevant to therapy	21
Intrinsic host defense against retroviruses	22
Interferon-induced B cell deletion in chronic viral infections.....	23
Drosha as an interferon-independent antiviral factor	23
Life cycle of virus as basis for antiviral approaches.....	23
Genetic switch in virus infections	24
Emerging viruses	25
Viral-induced cancer	26
Viral encephalitis	27
Antibody-mediated encephalitis	27
Brain's response to viral infections	27
Combination of antivirals with immunosuppression in viral encephalitis.....	28
Molecular diagnosis of viral diseases	28
Prophylaxis versus therapy.....	29
Economic impact of viral diseases	29
Historical landmarks in the development of antiviral therapies	29
2. Antiviral Approaches	31
Classification	31
Antiviral drug discovery and development.....	31
Antiviral drug targets – viral versus cellular	31
Antivirals based on double-stranded RNA activated caspase oligomerizer.....	33
Antimicrobial peptides	33
Human DDX3 protein as a target for developing broad spectrum antiviral agents.....	33
Immunological approaches.....	34
Basics of immune regulation in relation to viruses.....	34
<i>Effect of viruses on the immune system.....</i>	<i>34</i>
<i>Latent viral infections and the immune system</i>	<i>35</i>
Immunomodulating agents	35
<i>Amplification of innate immunity.....</i>	<i>35</i>
<i>Blocking the effects of thromboxane A2 on thromboxane receptor</i>	<i>36</i>
<i>Enhancers of immune system.....</i>	<i>36</i>
<i>Promoting immune-mediated clearance of a chronic viral infections.....</i>	<i>36</i>
<i>Immunoglobulins</i>	<i>37</i>
<i>Bovine lactoferrin.....</i>	<i>37</i>
<i>Quercetin.....</i>	<i>38</i>
Monoclonal antibodies	38
<i>Antibody production technologies.....</i>	<i>39</i>
<i>Bavituximab.....</i>	<i>39</i>
<i>Treatment of viral infection with radiolabeled MAbs</i>	<i>39</i>
<i>Limitations of MAbs and measures to overcome these</i>	<i>40</i>
Interferon-based approaches.....	40
Cholesterol-25-hydroxylase.....	41
Novel antiviral approaches	41
Phosphatidylethanolamine inhibitors as potential antivirals.....	41
Squalamine.....	41
Synthetic modified hypericin compounds.....	42
Targeting Toll-like receptors.....	42
<i>Potential and drawbacks of TLR-ligands in viral diseases</i>	<i>43</i>
Use of CRISPR/Cas9 gene editing in antiviral approaches.....	43
Inhibition of viral transport from cytoplasm into the cell nucleus.....	44
Nitric Oxide based antiviral therapeutics	44
Amino acid cognate anticodon binding specificity.....	44
Antisense approaches to viral infections.....	45
Antisense oligonucleotides	45
Limitations of antisense oligonucleotides as antivirals.....	46
Phosphorodiamidate morpholino oligomers.....	46
Gene therapy for viral infections.....	47

RNAi	47
RNAi screens of viral genomes.....	47
RNAi for treatment of viral infections.....	48
Promise and pitfalls of RNAi gene therapy	48
Role of proteomics in virology	49
Interaction of proteins with viruses	49
Quantitative temporal viromics	49
Management of rapidly evolving pathogens.....	50
Personalized medicine and viral diseases	50
An integrated approach to viral diseases	50
Current problems and needs in antiviral therapy	50
Immunoinformatic approach to vaccine design for emerging infections	51
3. Vaccines for Virus Infections	53
Introduction	53
Types of vaccines.....	54
DNA vaccines	54
Live attenuated virus vaccines.....	55
mRNA vaccines.....	55
Nanotechnology-based vaccines.....	56
<i>Nanobead adjuvants.....</i>	<i>56</i>
Recombinant viral vaccines	56
SMART vaccines.....	57
Synthetic peptides as vaccines	57
Virally vectored vaccines.....	58
Virosomes.....	59
Vaccines based on reverse genetics.....	59
Virus-like particles	59
Routine vaccination in children against viral infections	60
Personalized vaccines.....	60
Limitations of vaccines	61
Neurological complications of vaccination	61
Expert opinion on antiviral vaccines	62
4. Role of Nanotechnology in Developing Antiviral Agents.....	63
Introduction	63
Study of interaction of nanoparticles with viruses.....	63
Exosomes and viral infections.....	64
Nanoparticle antiviral agents.....	64
Silver nanoparticles.....	64
Fullerenes	64
Nanoparticles mimic RNAi for treatment of viral infections.....	65
Nanoviricides	65
Role of micelles in nanopharmaceuticals	65
Some physicochemical characteristics common to polymeric micelles	66
Structure and function of nanoviricides	66
<i>Mechanism of action of NanoViricides</i>	<i>66</i>
<i>Advantages of NanoViricides.....</i>	<i>68</i>
5. Delivery of Antivirals	71
Introduction	71
Methods of delivery of antiviral agents	71
Local application of antivirals.....	71
Systemic delivery of protein-polymer antiviral drugs.....	72
Controlled delivery of antivirals.....	72
Targeted delivery of antivirals	72
Delivery of antivirals to the brain across the blood-brain barrier	73
Antiviral vaccine delivery systems	73
Minicell vaccine delivery.....	73
Transnasal delivery of vaccines by Newcastle disease virus as vector	73
Transdermal delivery of vaccines	74
<i>Dissolvable microneedle array for vaccine delivery</i>	<i>74</i>
<i>Electroporation for administering DNA vaccines</i>	<i>74</i>
<i>HIV/AIDS vaccination by transdermal application.....</i>	<i>76</i>
<i>Microneedles for transdermal delivery of vaccines</i>	<i>76</i>
<i>Needle-free delivery of vaccines.....</i>	<i>76</i>
<i>Transdermal vaccines for influenza.....</i>	<i>77</i>
Use of nanotechnology for improving delivery of antivirals	78
Macrophage-based nanoformulated antiretroviral therapy	79
Improvement of antiviral vaccine delivery by nanotechnology.....	79
<i>Bacterial spores for delivery of vaccines.....</i>	<i>79</i>

<i>Chitosan-derived nanoparticles for vaccine delivery</i>	79
<i>Dendrimer-based intracellular delivery of antibodies</i>	80
<i>Gold nanorods for delivery of RNA immune activator molecules</i>	80
<i>Lipid nanoparticles for immunostimulatory RNA delivery</i>	80
<i>Liposomal antiviral vaccine preparations</i>	81
<i>Nanoparticles for DNA vaccines</i>	81
<i>Nanospheres for controlled release of viral antigens</i>	81
<i>Proteosomes™ as vaccine delivery vehicles</i>	82
<i>Polymeric micellae for delivery of DNA vaccine</i>	82
<i>"Smart" nanoparticles for delivery of vaccines</i>	82
Nanocoating for local viricidal effect	82
Delivery of gene-based antiviral drugs	83
Limitations of delivery of gene, RNAi and antisense therapies	83
Systemic delivery of NanoViricides	84
Concluding remarks on delivery of antiviral agents	84
6. Competitive Assessment of Antiviral Approaches	85
Introduction	85
An ideal antiviral agent	85
SWOT analysis	85
Concluding remarks	88
7. Influenza Viruses	89
Introduction	89
Clinical features of influenza	89
Colds due to rhinovirus	89
Effects of influenza on the respiratory system.....	90
Effect of avian influenza on the nervous system.....	90
Epidemiology	90
Supermap of avian influenza	90
Influenza A	91
Avian influenza affecting humans.....	91
<i>Human infection with a H7N9 Virus</i>	92
Human influenza versus avian influenza.....	92
H1N1 influenza	93
Immune system and influenza	94
Immune Epitope Database and Analysis Resources	95
Role of Tpl2 in antiviral host defense mechanisms.....	95
Anti-influenza approaches	96
Pharmaceuticals.....	96
Neuraminidase inhibitors	96
<i>Mechanism of action</i>	96
<i>Tamiflu</i>	97
<i>Zanamivir</i>	97
<i>CS-8958</i>	97
<i>Peramivir</i>	98
<i>Resistance to neuraminidase inhibitors</i>	99
<i>Adverse effects of neuraminidase inhibitors</i>	99
<i>Concluding remarks on neuraminidase inhibitors</i>	100
Other drugs for influenza	100
<i>Adamantanes</i>	100
<i>Baloxavir marboxil</i>	101
<i>Probenecid</i>	101
Current recommendations for the use of antiviral agents for influenza	101
Vaccines	102
<i>Seasonal influenza vaccines</i>	102
<i>Live attenuated influenza vaccine vs. inactivated vaccine</i>	103
<i>Recombinant influenza vaccine</i>	103
<i>Vaccines for H1N1 influenza</i>	103
<i>Vaccines for H7N9 influenza</i>	104
Current status of influenza vaccines	105
<i>Current recommendations for influenza vaccination</i>	105
<i>Current status of vaccine preparedness against seasonal influenza</i>	105
<i>Current status of vaccine preparedness against H5N1</i>	105
Limitations, needs and challenges of influenza vaccines	106
<i>Limitations of current influenza vaccines</i>	106
<i>Needs of influenza vaccines</i>	106
<i>Problems with demand and supply of influenza vaccines</i>	107
<i>Problems with access to virus samples</i>	108
<i>FluVac project for development of pandemic influenza vaccine</i>	108
<i>Influenza vaccines for multiple strains of influenza</i>	108

<i>Quadrivalent influenza vaccine</i>	109
<i>Universal influenza vaccines</i>	109
<i>Future of influenza vaccines</i>	110
Application of new technologies for influenza vaccines	110
<i>Adjuvants</i>	111
<i>Cell culture-derived influenza vaccines</i>	112
<i>DNA vaccines for avian influenza</i>	113
<i>Epitope-based vaccines for influenza</i>	113
<i>Gene-based vaccines for influenza</i>	114
<i>Live attenuated vaccines</i>	114
<i>MABs for passive immunization against avian influenza</i>	114
<i>M2e-based human influenza A vaccine</i>	114
<i>RNA vaccines against influenza A</i>	115
<i>Pre-pandemic split antigen H5N1 vaccine</i>	115
<i>Recombinant-protein based influenza vaccines</i>	116
<i>Synthetic avian influenza vaccine</i>	117
<i>Viral vectors for influenza vaccination</i>	117
<i>Virus-like particles as influenza vaccines</i>	117
RNAi-based approaches	119
<i>Inhibition of influenza virus by siRNAs</i>	119
<i>Limitations of RNAi approach to influenza</i>	119
<i>Challenges and future prospects of siRNAs for influenza</i>	120
Antisense approaches.....	120
<i>NEUGENE® antisense for inhibition of multiple strains of influenza A</i>	120
Nanoviricides against influenza	121
Other innovative approaches	122
<i>Abatacept</i>	122
<i>Polymeric coatings to inactivate influenza virus</i>	122
<i>Cytotoxic therapy</i>	122
<i>Cyanovirin</i>	123
<i>Fludase</i>	123
<i>Multiferon®</i>	123
<i>Pyrrrolidine dithiocarbamate</i>	123
<i>Value of antivirals in preventing spread of influenza after exposure</i>	124
<i>Resistance to influenza therapy and efforts to overcome it</i>	124
FLUCURE project.....	125
NIAID Centers of Excellence for research on pandemic influenza viruses.....	125
Research on influenza viruses at Bayer	125
Concluding remarks and future	126

8. AIDS/HIV	127
Introduction	127
Epidemiology	127
Current concepts of pathomechanisms	127
Decoding the structure of an entire HIV genome	128
Genetic basis of resistance against HIV.....	128
Host-pathogen interactions that regulate HIV-1 replication.....	128
Pathogenesis of AIDS	129
Visualization of the interaction of HIV-1 proteins with target cells	130
Viral latency in HIV	130
Complications of AIDS	130
AIDS and the nervous system	130
AIDS wasting syndrome.....	131
Coexistent HIV-1 and HSV-2	131
Coexistent hepatitis virus infections with HIV	132
<i>HIV and HBV</i>	132
<i>HIV and HCV</i>	132
Opportunistic infections in AIDS.....	133
<i>HIV and tuberculosis</i>	134
Current therapies.....	134
Aim of anti-HIV drugs.....	135
Nucleoside reverse transcriptase inhibitors.....	136
Non-nucleoside reverse transcriptase inhibitors	136
<i>Efavirenz</i>	136
<i>Etravirine</i>	137
Protease inhibitors	137
<i>Tipranavir</i>	137
<i>Darunavir</i>	137
Fusion inhibitors	138
<i>Enfuvirtide</i>	138
Impact of antiretroviral treatment on transmission of HIV.....	138

Preexposure prophylaxis against HIV.....	139
Postexposure prophylaxis against HIV	139
Antiretroviral therapy in early asymptomatic HIV infection	140
Limitations of current therapies.....	140
Adverse effects of antiretroviral therapy	140
Drug resistance in AIDS.....	141
Effect of interruption of HIV treatment.....	142
Reservoirs of HIV Infection.....	142
Persistence of low-level viremia in HIV-1 patients on retroviral therapy	142
Reconsideration of abandoned therapies for AIDS.....	143
Therapies in development.....	143
Drugs in development for HIV/AIDS	143
<i>NRTIs in development</i>	144
<i>NNRIs in development</i>	144
Novel protease inhibitors	145
<i>Overcoming HIV-1 resistance to PIs</i>	145
<i>PPL-100</i>	146
Entry inhibitors targeting CCR5 receptor	146
<i>Maraviroc</i>	147
<i>SP-01A</i>	147
<i>MABs targeting CCR5 receptor</i>	147
<i>PRO 140</i>	148
<i>Ibalizumab</i>	148
Integrase inhibitors.....	149
<i>Raltegravir (Isentress)</i>	149
<i>Elvitegravir</i>	150
<i>Dolutegravir</i>	150
<i>S/GSK1265744</i>	150
<i>LEDGINS</i>	151
Design of fusion inhibitor peptides against enfuvirtide-resistant HIV-1	151
Maturation inhibitors	151
Blocking of pre-integration complex translocation	152
Immune enhancers	152
Pyrimidinediones.....	153
Combinations of drugs for AIDS	153
<i>Truvada</i>	153
<i>Raltegravir, enfuvirtide, and darunavir</i>	154
Other innovative antiviral approaches against HIV/AIDS	154
A filtration device for HIV-1 as an adjunct to the immune system	154
Anti-HIV therapies based on editing enzymes	154
Anti-HIV activity of drugs that stimulate cholesterol efflux	154
Antiviral hyperactivation-limiting therapeutics	154
ATR kinase as a target for anti-HIV drug discovery.....	155
Blocking of HIV budding by DC-SIGN protein.....	155
Drugs from natural sources	155
Enhancing immune response by blockade of PD-1 receptor	156
IL-2 as adjunct to antiretroviral therapy	156
In vitro evaluation of antiviral drug activity	156
Methods for sustaining antiviral activity	157
Microbical agents for local application in HIV/AIDS	157
<i>Investigational microbicals against HIV and their limitations</i>	158
<i>CCR5 receptor blockers</i>	158
<i>PSC-Rantes and recombinant chemokine analogs</i>	159
<i>HIV-1 entry inhibitor griffithsin as a topical microbicide</i>	159
<i>Nanotechnology-based topical microbicides</i>	159
<i>Next generation microbicides for HIV</i>	160
<i>Vaginal application of anti-retroviral drugs against HIV</i>	160
Nanoviricides for HIV/AIDS	160
Prophylactic measures to prevent HIV infection	161
Selective targeting of ITK to block multiple steps of HIV replication	161
T cell receptors from HIV controllers.....	162
Cell therapy for HIV/AIDS	162
hESCs converted to T cells for treatment of HIV infection.....	162
Transplantation of genetically modified hematopoietic cells	162
Transplantation of genetically modified T cells	163
Overlapping Peptide-pulsed Autologous Cells.....	163
Gene therapy strategies in HIV/AIDS	164
Gene editing for HIV-1.....	164
Inhibition of HIV-1 replication by lentiviral vectors	165
VRX496-T (Lexgenleucel-T).....	165
Insertion of protective genes into target cells	166

Use of genes to chemosensitize HIV-1 infected cells	166
Autocrine interferon- β production by somatic cell gene therapy	166
Intracellular immunization in HIV	166
<i>Engineered cellular proteins such as soluble CD4s</i>	167
<i>Intracellular antibodies</i>	167
<i>Selection of T cell vaccine antigens</i>	167
<i>Glycoprotein 120 as target for neutralizing HIV-1 antibodies</i>	167
<i>Anti-rev single chain antibody fragment</i>	168
HIV/AIDS vaccines	168
<i>Cell-based vaccines for HIV</i>	169
<i>Delivery of HIV vaccine by an adenoviral vector</i>	169
<i>DNA vaccines for HIV/AIDS</i>	170
<i>Epitope-based DNA vaccines against HIV</i>	171
<i>Gene transfer for HIV vaccination</i>	171
<i>Recombinant HIV proteins</i>	171
<i>Vaccination after discontinuation of antiretroviral treatment</i>	172
Innovations in HIV/AIDS vaccine	172
<i>Attenuated rabies virus-based vaccine for HIV</i>	172
<i>Dendritic cell-based vaccine for HIV</i>	172
<i>DermaVir</i>	173
<i>Early control of HIV by an effector memory T cell vaccine</i>	173
<i>Immunogens for inducing broadly neutralizing antibodies</i>	173
<i>MVA nef vaccine</i>	174
<i>Peptide-based vaccine for HIV</i>	174
<i>Personalized vaccine for HIV</i>	174
<i>RV144 HIV vaccine trial</i>	175
<i>Transdermal nanoparticles for immune enhancement in HIV</i>	175
<i>Vaccine to prevent HIV entry at the mucosal level</i>	175
Limitations and future of HIV vaccines	176
Antisense approaches to AIDS	177
<i>Antisense oligodeoxynucleotides</i>	177
<i>Antisense efforts with PNA constructs</i>	177
<i>RNA decoys</i>	178
<i>Ribozymes</i>	178
RNAi applications in HIV/AIDS	179
<i>A multiple shRNA approach for silencing of HIV-1</i>	179
<i>Aptamer-mediated delivery of anti-HIV siRNAs</i>	179
<i>Bispecific siRNA constructs</i>	180
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	180
<i>siRNA-directed inhibition of HIV-1 infection</i>	180
<i>Synergistic effect of snRNA and siRNA</i>	182
<i>Targeting CXCR4 with siRNAs</i>	182
<i>Targeting CCR5 with siRNAs</i>	182
<i>Concluding remarks on RNAi approach to HIV/AIDS</i>	183
Companies involved in developing gene therapy for HIV/AIDS	183
Conclusions regarding gene therapy of HIV/AIDS.....	184
Testing for new anti-HIV therapies.....	184
Personalized approach to management of HIV	185
Differences in response of the body to HIV	185
Variations in action of drugs on HIV	185
<i>Drug-resistance in HIV</i>	186
<i>PhenoSense® to test HIV drug resistance</i>	186
<i>Role of biomarkers in management of HIV/AIDS</i>	186
<i>Role of diagnostic testing in management of HIV</i>	187
<i>Prevention of adverse reactions to antiviral drugs</i>	187
<i>Nanoviricides as a personalized approach to HIV</i>	188
Concluding remarks and future.....	188
9. Hepatitis Viruses	191
Introduction	191
Hepatitis delta virus infection	191
Hepatitis A virus infection.....	191
Hepatitis E virus infection	192
Epidemiology.....	192
Structure of the HEV	192
Treatment of HEV infection	192
<i>Ribavirin</i>	192
<i>Zinc as a potential anti-HEV agent</i>	193
<i>Vaccines for hepatitis E</i>	193
Epidemiology of HBV.....	193
Pathogenesis of HBV-induced liver disease.....	194

Current approaches to management of HBV	194
Entecavir	195
Adefovir dipivoxil	195
Telbivudine	195
Pegylated interferon-alpha	196
Limitations of current therapies and needs of HBV	196
Personalized management of HBV	196
Innovations in the management of HBV	197
Tenofovir disoproxil fumarate	197
Hepatitis B immune globulins	197
<i>Nabi-HB</i>	197
<i>HepaGam B</i>	198
Hepatitis B vaccine composed in a novel nanoemulsion adjuvant	198
Innovative pharmaceuticals for HBV	198
<i>AGX-1009</i>	199
<i>Clevudine</i>	199
<i>Helioxanthin analog 8-1</i>	199
<i>HepDirect prodrugs</i>	199
Monoclonal antibodies for HBV.....	199
RNAi-based therapy of HBV.....	200
Personalized treatment of hepatitis B	200
Concluding remarks and future prospects of management of hepatitis B	201
Epidemiology of HCV.....	201
HCV characteristics.....	202
Pathomechanism of HCV infection	202
Mechanism of HCV entry.....	202
HCV and the immune system	202
Mechanism of HCV replication and response to interferon.....	203
Current approaches to management of HCV	203
Interferon therapy for HCV.....	203
Limitations of current HCV therapies	204
Novel approaches to HCV.....	204
HCV protease inhibitors	205
<i>ABT-450</i>	205
<i>Boceprevir</i>	205
<i>Combined daclatasvir and asunaprevir</i>	205
<i>Faldaprevir</i>	206
<i>Glecaprevir/pibrentasvir combination</i>	206
<i>Narlaprevir</i>	206
<i>Sofosbuvir</i>	206
<i>Simeprevir</i>	207
<i>Small molecule HCV protease inhibitors</i>	207
<i>Telaprevir</i>	207
Innovations in interferon therapy for HCV	208
<i>AlbIFN-α2b</i>	208
<i>Directed evolution of gene-shuffled IFN-α for treatment of HCV</i>	208
<i>GEA007.1</i>	208
<i>Omega DUROS</i>	209
<i>PEG-IFN-λ</i>	209
<i>Personalizing interferon therapy of HCV</i>	210
Innovative ribavirin-based treatments	210
<i>Targeted delivery of hemoglobin-ribavirin conjugate for HCV</i>	210
<i>Taribavirin</i>	210
Nucleoside polymerase inhibitor.....	211
<i>Deleobuvir</i>	211
<i>Valopicitabine</i>	211
Host cell targets for hepatitis C therapy	211
<i>SP-10</i>	212
NS5a inhibitors.....	212
<i>Ledipasvir</i>	212
NS5b inhibitors.....	212
Novel combination of a protease inhibitor and a NS5a inhibitor	213
<i>Zepatier™</i>	213
Compounds targeting HCV receptor E2	213
Cyclophilin inhibitors	213
<i>Alisporivir</i>	214
Methylene blue	214
Naringenin	214
Nitazoxanide	215
Cyclosporine and analogs as anti-HCV agents.....	215
Clemizole and HCV.....	216

RNAi-based approaches to HCV	216
<i>Use of adenoviral vectors for RNAi</i>	216
<i>siRNAs for HCV</i>	217
<i>Limitations and drawbacks of siRNA therapy for HCV</i>	217
<i>Role of miRNA in viral infections</i>	218
<i>miR-122 antagonists</i>	218
Gene therapy for HCV	218
Vaccines for HCV	219
<i>HCV vaccine based on viral vectors to boost T cell memory</i>	219
<i>Vaccine based on neutralizing antibodies to HCV</i>	219
Clinical trials of HCV therapeutics	220
Limitations to the development of effective anti-HCV therapeutics	220
<i>Causes of treatment failure in chronic hepatitis C</i>	221
<i>HCV drug resistance</i>	221
Personalized management of HCV infection	221
Role of sequencing in personalized management of HCV	222
Concluding remarks about HCV therapy	223
Drug combinations for HCV	223
IFN-free combinations for HCV	223
Search for new drugs for HCV	224
Future needs in HCV therapy	224
10. Miscellaneous Commercially Important Virus Infections	227
Introduction	227
Herpes viruses	227
Neuroinvasive herpesviruses	227
Herpes simplex virus	227
Treatment of HSV-1	227
<i>Acyclovir</i>	227
<i>Vaccines for HSV</i>	228
<i>Antisense therapy for HSV-1</i>	228
Herpes simplex virus 2 and genital herpes	229
<i>Famciclovir</i>	229
<i>Pritelivir</i>	229
<i>Intravaginal microbicidal agents for HSV-2</i>	229
<i>Vaccines for HSV-2</i>	230
Herpes simplex keratitis	230
Herpes simplex encephalitis	231
Limitations of current HSV therapies	231
<i>Genomic diversity of HSV-1 as a cause of failure of vaccines</i>	231
Herpes zoster virus	232
<i>Herpes zoster and chicken pox</i>	232
<i>Epidemiology of herpes zoster</i>	232
<i>Treatment of herpes zoster</i>	232
<i>Herpes zoster vaccines</i>	233
Epstein-Barr virus	233
Latent herpes virus infection	234
Cytomegalovirus	234
Current treatment of CMV	235
<i>Brincidofovir (CMX001)</i>	235
<i>Valganciclovir hydrochloride</i>	235
<i>Limitations of current treatment and future</i>	235
Letermovir	235
T cell therapy for CMV	236
Vaccines for CMV	236
Gene therapy of CMV	237
Antisense approach to CMV	237
siRNA treatment of CMV	238
Human papilloma virus	238
Epidemiology	238
Vaccines for HPV	239
<i>Gardasil</i>	239
<i>Cervarix</i>	239
<i>DNA vaccine VGX-3100</i>	240
<i>GTL001 and GTL002</i>	240
<i>Vaccine based on fusion proteins of HPV envelope</i>	240
<i>Limitations of HPV vaccines</i>	240
Antivirals for HPV	241
<i>Imiquimod</i>	241
Novel approaches against HPV	242
<i>Intrabody strategies for the treatment of HPV</i>	242

<i>A novel peptide to inhibit HPV</i>	242
<i>Heat shock protein-based antivirals</i>	242
Respiratory syncytial virus	243
Epidemiology.....	243
Current management of RSV	243
<i>Palivizumab</i>	244
<i>MDT-637</i>	244
<i>GS-5806</i>	244
<i>RNAi approach to RSV</i>	244
<i>Other approaches to RSV antivirals</i>	245
Vaccines for RSV.....	245
<i>BCG as a vaccine against RSV</i>	245
<i>Oral DNA vaccine for RSV</i>	246
<i>Neutralizing antibodies against preactive form of hRSV_F protein</i>	246
Challenges for development of RSV antivirals	246
Other respiratory viruses	246
Parainfluenzavirus type 3	246
Human metapneumovirus	247
Gastrointestinal viruses	247
Noroviruses.....	247
<i>Potential for development of antiviral agents against noroviruses</i>	248
<i>Vaccines against noroviruses</i>	248
Concluding remarks	249

11. Viruses with High Impact but Low Commercial Significance 251

Introduction	251
Chikungunya fever	251
Chikungunya antiviral therapy	252
Chikungunya vaccines	252
Enteroviruses	252
Enterovirus 71	252
Coxsackie virus.....	253
Japanese encephalitis	253
Vaccines for JE	253
Parvovirus	254
Polyomavirus JC	254
Rabies	255
Rabies vaccines	255
<i>Recombinant viral vaccines for rabies</i>	256
DNA vaccine against rabies	256
Rabies immune globulin.....	256
Monoclonal antibodies for rabies	256
NanoViricides approach for rabies	257
Protein-protein interactions as targets for antirabies drug discovery	257
siRNA-based approach against rabies	257
The Milwaukee protocol for rabies	258
Rotavirus	258
Epidemiology.....	258
Rotavirus genome	258
Vaccines against rotavirus.....	259
Viral hemorrhagic fevers	260
Bas-Congo virus associated with acute hemorrhagic fever.....	261
Crimean-Congo hemorrhagic fever	261
Dengue.....	262
<i>Epidemiology</i>	262
<i>Antivirals in development against dengue</i>	263
<i>Dengue vaccines</i>	264
<i>Dengvaxia</i>	265
<i>Elimination of dengue vector mosquitoes by fungus</i>	266
<i>Genetic elimination of dengue vector mosquitoes</i>	267
Ebola virus.....	267
<i>Pathogenesis and diagnosis of Ebola virus</i>	268
<i>Sequencing of the Ebola genome</i>	268
<i>Antiviral approaches to Ebola virus infection</i>	269
<i>Antivirals for Ebola based on inhibition of RNA polymerase</i>	270
<i>Cell entry blockers as antivirals for filoviruses</i>	270
<i>Development of RNAi-based antiviral drugs for Ebola</i>	271
<i>EbolaCide</i>	271
<i>Monoclonal antibody immunotherapy for Ebola</i>	272
<i>Vaccines for Ebola</i>	272
<i>Ebola whole virus vaccine</i>	274

<i>Companies developing antivirals against Ebola</i>	275
<i>Concluding remarks and future</i>	275
Human hanta viruses	276
Lassa fever	277
Marburg hemorrhagic fever	277
<i>Therapies in development against Marburg virus</i>	277
Yellow fever	278
<i>Vaccines for yellow fever</i>	278
<i>Sequencing of Aedes aegypti genome and control of yellow fever</i>	279
West Nile virus	279
Epidemiology	279
Pathogenesis	279
Treatment of West Nile neuroinvasive disease	280
Vaccines against WNV	280
Innovative treatments for WNV	280
Zika virus	281
Introduction to Zika virus	281
ZIKV in the USA	282
Clinical features of ZIKV	282
Molecular epidemiology of ZIKV	282
Molecular diagnosis of ZIKV infection	282
Neurological complications of ZIKV infection	283
<i>Microcephaly</i>	283
<i>Guillain-Barré syndrome</i>	284
Prevention and treatment of ZIKV infection	284
<i>Antiviral agents against ZIKV</i>	284
<i>Preventive measures against ZIKV infection</i>	285
<i>Vaccines for ZIKV</i>	285
<i>WHO views on challenges in management of ZIKV</i>	287
Western equine encephalitis	288
Tick-borne encephalitis	288
TBE vaccines	288
Human coronaviruses	288
SARS	288
<i>Therapeutic approaches to SARS</i>	289
<i>MABs for SARS</i>	289
<i>siRNA treatment of SARS</i>	290
Middle East respiratory syndrome coronavirus	290
<i>Development of therapeutics for MERS-CoV</i>	292
<i>MERS vaccines</i>	293
<i>Future directions for management of MERS</i>	294
Measles	294
Zoonotic viral infections	295
Nipah virus	295
Vaccines for zoonotic viral diseases	295
Virus bioterrorism and biowarfare	296
Small pox as a biological weapon	296
<i>Status of small pox vaccination</i>	296
Strategies against virus bioterrorism and biowarfare	297
<i>Increasing resistance by stimulating innate immune mechanisms</i>	297
<i>Nanoviricides for combating viral bioterrorism</i>	297
Concluding remarks	298
12. Markets for Antivirals	299
Introduction	299
Markets according to disease	299
Influenza market	299
HIV/AIDS market	300
Hepatitis B and C markets	301
<i>Economics of care of hepatitis C and impact on the market</i>	301
Markets for diseases with low commercial significance	301
Markets according to products and approaches	302
Market values of monoclonal antibodies for viral diseases	302
Market values of vaccines for viral diseases	302
Markets for vaccines against HPV	303
Research investment and potential markets for HIV/AIDS vaccines	303
Markets for other antiviral vaccines	303
Markets according to geographical areas	303
Emerging markets for antiviral therapeutics	304
Geographical distribution of HIV/AIDS market	305
Unmet needs in antivirals	305

Policies regarding conquered viral diseases	306
Future of polio vaccine.....	306
Policies concerning HPV vaccine for prevention of cervical cancer	307
<i>HPV vaccine in developing countries.....</i>	<i>307</i>
Future prospects of innovative approaches	308
US Government support of antiviral efforts.....	309
<i>US Government support for R & D in avian influenza vaccines</i>	<i>309</i>
<i>US Government support for developing anti-bioterrorism agents.....</i>	<i>309</i>
The European Union support of antiviral research	310
<i>European Commission's research support for anti-HIV/AIDS programs</i>	<i>310</i>
<i>European Commission's support anti-influenza programs</i>	<i>311</i>
Collaboration of biotechnology companies with big pharma	312
Strategies for marketing.....	312
13. Companies	313
Introduction	313
Top companies.....	313
Profiles of pharmaceutical companies.....	314
Profiles of biopharmaceutical companies with antiviral products	330
Profiles of antiviral drug companies	417
Profiles of viral vaccine companies	446
Collaborations.....	528
14. References.....	535

Tables

Table 1-1: A practical classification of viruses.....	20
Table 1-2: Viruses causing encephalitis	27
Table 1-3: Vaccines vs therapeutics for viral diseases.....	29
Table 1-4: Historical landmarks in the development of antiviral therapies	29
Table 2-1: Classification of antiviral strategies.....	31
Table 2-2: Viral vs cellular targets for discovery of antivirals	32
Table 2-3: Viruses amenable to antisense oligonucleotides	45
Table 2-4: Inhibition of viral replication by RNAi	48
Table 3-1: Types of vaccines for viral diseases	54
Table 4-1: Role of nanobiotechnology in virology	63
Table 5-1: Methods of delivery of antiviral agents	71
Table 5-2: Role of nanotechnology for improving delivery of antivirals.....	78
Table 5-3: Commercially available liposomal antiviral vaccines	81
Table 6-1: SWOT of monoclonal antibodies	85
Table 6-2: SWOT of agents that prevention viral entry into cells	86
Table 6-3: SWOT of drugs interfering with intracellular replication	86
Table 6-4: SWOT of protease inhibitors	86
Table 6-5: SWOT of integrase inhibitors	86
Table 6-6: SWOT of maturation inhibitors	86
Table 6-7: SWOT of neuraminidase inhibitors.....	87
Table 6-8: SWOT of targeting Toll-like receptors (TLRs).....	87
Table 6-9: SWOT of topical antivirals agents against viral infections.....	87
Table 6-10: SWOT of gene therapy, antisense oligonucleotides, RNAi	87
Table 6-11: SWOT of vaccines.....	87
Table 6-12: SWOT of NanoViricides.....	88
Table 7-1: Anti-influenza approaches	96
Table 7-2: Antiviral drugs used for influenza	96
Table 7-3: Various approaches to production of influenza vaccines.....	111
Table 8-1: Drugs in clinical development for HIV/AIDS	143
Table 8-2: Strategies for gene therapy of AIDS	164
Table 8-3: Classification of HIV/AIDS vaccines in clinical trials.....	168
Table 8-4: Companies involved in developing gene therapy for HIV/AIDS	183
Table 9-1: Innovations in the treatment of HBV	197
Table 9-2: Innovations for management of HCV	204
Table 9-3: Antiviral agents for HCV targeting host cells	211
Table 9-4: HCV drugs in clinical trials	220
Table 10-1: Methods of delivery of acyclovir.....	228
Table 11-1: Antiviral strategies against Ebola virus infection	269
Table 11-2: Companies developing antiviral products against Ebola	275
Table 11-3: ZIKA vaccines in development.....	286
Table 11-4: Strategies against virus bioterrorism and biowarfare.....	297
Table 12-1: Worldwide market for all antiviral approaches 2017-2027	299

Table 12-2: Markets for antiviral drugs according to virus infections 2017-2027	299
Table 12-3: Markets values of all drugs for HIV/AIDS 2017-2027	300
Table 12-4: Market values of monoclonal antibodies for viral diseases 2017-2027	302
Table 12-5: Market values of vaccines for viral diseases 2017-2027	302
Table 12-6: Markets for antiviral drugs according to geographical areas 2017-2027	304
Table 12-7: Markets for antiviral vaccines according to geographical areas 2017-2027	304
Table 12-8: Emerging markets for antiviral drugs according to countries 2017-2027	304
Table 12-9: Emerging markets for antiviral vaccines according to countries 2017-2027	305
Table 13-1: Top antiviral companies	313
Table 13-2: Roche antiviral products in development	320
Table 13-3: Collaborations of antiviral companies	528

Figures

Figure 1-1: Varieties of host and cell responses to viral infections	22
Figure 1-2: Cycle of infection and replication of a retrovirus	24
Figure 1-3: Viral-induced cancer	26
Figure 2-1: An integrated approach to viral diseases	50
Figure 4-1: Schematic representation of NanoViricide attacking a virus particle	68
Figure 7-1: Evolution of mutations associated with virulence/drug resistance in H5N1	93
Figure 7-2: Mechanism of development of resistance to oseltamivir	99
Figure 8-1: Mode of action of some current anti-HIV drugs	135
Figure 8-2: Nanocarrier-mediated siRNA delivery for treatment of HIV/AIDS	182
Figure 9-1: Steps of HBV replication and site of action of various drugs	194
Figure 9-2: Omega DUROS device for interferon delivery in chronic hepatitis C	209
Figure 11-1: Ebola virus	267
Figure 11-2: Strategies for development of ZIKV vaccines	286
Figure 11-3: Transmission and pathogenesis of MERS-CoV	292
Figure 12-1: Unmet needs in antivirals	306